(Q28365888)

ORCID Public Data File 2021

author name string

G Corona

2

0 references

R Sorio

3

0 references

I Robieux

4

0 references

B Basso

5

0 references

A M Colussi

6

0 references

M Boiocchi

British Journal of Clinical Pharmacology

7

0 references

language of work or name

English

0 references

publication date

November 2001

0 references

published in

0 references

volume

52

0 references

issue

5

0 references

page(s)

511-9

0 references

cites work

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Effects of aging on the renal glomerulus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Pharmacodynamics in cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

The pharmacology of intravenous and oral etoposide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Oral etoposide in small cell lung cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Letter: Creatinine clearance: bedside estimate.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Population pharmacokinetics of mitoxantrone performed by a NONMEM method

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Etoposide kinetics in patients with obstructive jaundice

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

Population pharmacokinetics of total and unbound etoposide.

2 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01468.X

A limited sampling model for the pharmacokinetics of etoposide given orally.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01468.X

Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01468.X

Etoposide pharmacokinetics in patients with normal and abnormal organ function

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014597

A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer

27 November 2018

1 reference

12 December 2020

Changes in the clearance of total and unbound etoposide in patients with liver dysfunction

1 reference

12 December 2020

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

12 December 2020

Variability in the pharmacokinetics of epirubicin: a population analysis

1 reference

12 December 2020

Phase II study of oral VP-16-213 in hepatocellular carcinoma

1 reference

12 December 2020

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function

1 reference

12 December 2020

Altered protein binding of etoposide in patients with cancer

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results

1 reference

12 December 2020

Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results

1 reference

12 December 2020

Predicting etoposide toxicity: relationship to organ function and protein binding

1 reference

12 December 2020

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer

1 reference

12 December 2020

Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection

1 reference

12 December 2020

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer

1 reference

12 December 2020